Initial Management of Hepatic Steatosis

Risk Stratification

The American Association for the Study of Liver Diseases recommends patients be stratified into risk categories based on fibrosis assessment to determine appropriate management approach, using the FIB-4 score as first-tier assessment, with low risk defined as FIB-4 <1.3, intermediate risk as FIB-4 1.3-2.67, and high risk as FIB-4 >2.67 3

The American Heart Association recommends a hypocaloric diet with 500-1000 kcal energy deficit to achieve weight loss of 500-1000g/week, with a target weight loss of at least 3-5% to improve steatosis, and 7-10% weight loss needed to improve inflammation and fibrosis 1, 2
The American Diabetes Association recommends a Mediterranean dietary pattern with vegetables, fruits, fiber-rich cereals, nuts, fish, white meat, and olive oil, and avoiding fructose-containing beverages, sugar-sweetened drinks, and ultra-processed foods rich in sugars and saturated fat 1, 2
The World Health Organization recommends at least 150-300 minutes/week of moderate-intensity or 75-150 minutes/week of vigorous-intensity physical activity, and limiting alcohol consumption below risk threshold (30g for men, 20g for women) or considering complete abstinence 1, 2

The American Diabetes Association recommends screening and managing cardiometabolic risk factors, including diabetes, dyslipidemia, and hypertension, and considering GLP-1 receptor agonists (e.g., semaglutide, liraglutide) for patients with diabetes, which can improve both glycemic control and liver histology 1, 2
The European Association for the Study of the Liver recommends considering SGLT2 inhibitors for patients with diabetes and hepatic steatosis, and avoiding sulfonylureas and insulin if possible, as they may increase the risk of hepatocellular carcinoma 1, 2
The American College of Cardiology recommends statins as safe and recommended for dyslipidemia management in patients with hepatic steatosis 1, 2

The American Association for the Study of Liver Diseases recommends obtaining baseline liver evaluation, including complete blood count, liver panel, international normalized ratio, and creatinine, and repeating liver function tests and non-invasive fibrosis assessment in 6-12 months for low-risk patients, and more frequent monitoring and referral to hepatology for intermediate/high-risk patients 2, 3

The American Gastroenterological Association recommends avoiding medications that may worsen steatosis, such as corticosteroids, amiodarone, methotrexate, tamoxifen, estrogens, tetracyclines, and valproic acid, and considering bariatric surgery in appropriate individuals with clinically significant fibrosis and obesity with comorbidities 2
The European Association for the Study of the Liver recommends patients with liver cirrhosis associated with NAFLD to have HCC surveillance, and nearly 10% of screened patients will have high risk of clinically significant liver fibrosis and should be managed by a multidisciplinary team coordinated by a hepatologist 1, 2

The American Association for the Study of Liver Diseases recommends gradual weight loss (maximum 1kg/week) to improve NASH and NAFLD activity score, while rapid weight loss may worsen liver disease, and pharmacological treatment should be reserved for patients with progressive NASH (bridging fibrosis and cirrhosis), not for simple steatosis 1
The American Gastroenterological Association recommends metformin is not recommended as a specific treatment for liver disease in adults with NASH as it has no significant effect on liver histology, and CT has limitations in evaluating hepatic steatosis in patients with infiltrative liver diseases that deposit iron, copper, glycogen or amiodarone in the liver parenchyma 1, 5